ESC 2024 atrial fibrillation guidelines: key recommendations

Who it applies to

Adults with newly diagnosed or established atrial fibrillation, including those being considered for anticoagulation, rate or rhythm control, or catheter/surgical ablation.

Key recommendations

• Use the AF-CARE framework (Comorbidity and risk factor management, Avoiding stroke, Reducing symptoms, Evaluation and dynamic reassessment) to structure care rather than treating stroke prevention in isolation.
• Base stroke risk assessment on individual risk factors rather than relying solely on a cutoff score, moving away from rigid CHA2DS2-VA thresholds toward shared decision-making informed by absolute risk factors.
• Offer oral anticoagulation to most patients with AF and at least one stroke risk factor, favouring direct oral anticoagulants over vitamin K antagonists except where DOACs are contraindicated, such as mechanical prosthetic heart valves or moderate-to-severe mitral stenosis.
• Avoid combining aspirin with oral anticoagulation for stroke prevention in AF unless there is a separate indication such as recent coronary stenting.
• Actively manage modifiable risk factors and comorbidities, including hypertension, obesity, physical inactivity, alcohol excess, and obstructive sleep apnoea, as a core part of AF management rather than an adjunct.
• Consider early rhythm control, including catheter ablation, in appropriately selected patients soon after diagnosis, reflecting evidence that early intervention can reduce progression and improve outcomes compared with delayed rhythm control.
• Recommend catheter ablation as first-line rhythm control therapy in selected patients with paroxysmal AF, including as an alternative to antiarrhythmic drugs, given its superior efficacy at maintaining sinus rhythm.
• Use a rate control strategy with beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin for patients in whom rhythm control is not pursued or not tolerated, individualising target heart rate.
• Reassess stroke and bleeding risk periodically rather than only at diagnosis, since risk factors and anticoagulation suitability can change over time.
• Consider left atrial appendage occlusion in patients with a clear contraindication to long-term oral anticoagulation and an appropriate indication for stroke prevention.

What is new in this edition

• Introduction of the AF-CARE framework replacing the previous ABC (Atrial fibrillation Better Care) pathway as the organising structure for management.
• Transition from the CHA2DS2-VASc score to the CHA2DS2-VA score, removing female sex as a separate risk factor from stroke risk calculation.
• Stronger emphasis on risk factor and comorbidity management as a foundational pillar rather than an adjunct to anticoagulation and rhythm control.
• Greater support for early rhythm control and catheter ablation as first-line therapy in suitable patients rather than reserving ablation for drug-refractory cases.
• Shift toward individualised, dynamic stroke risk assessment rather than fixed score-based cutoffs for anticoagulation decisions.

Practice points for students

• Remember AF-CARE as the exam-friendly mnemonic replacing ABC: it foregrounds comorbidity management alongside stroke and symptom control.
• Know that CHA2DS2-VA has replaced CHA2DS2-VASc, with female sex no longer counted as an independent risk factor in the scoring system.
• DOACs remain preferred over warfarin in eligible patients; know the key exceptions (mechanical prosthetic heart valves and moderate-to-severe mitral stenosis).
• Aspirin alone or added to anticoagulation is not a stroke prevention strategy in AF unless there is a concurrent indication like recent stenting.
• Catheter ablation has moved toward a first-line option in selected paroxysmal AF rather than strictly second-line after drug failure.

Condition

Other guidelines on this topic

• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesAHA/ACC2024Summary
• Atrial fibrillation: diagnosis and management (NG196)NICE2021Summary
• Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel ReportCHEST2018Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by ESC. It is not medical advice: always read the original guideline before applying it to patients.